CD4+ regulatory T (Treg) cells play a major role in limiting anti-tumor immunity, and Treg cell accumulation in tumors is often negatively associated with clinical outcomes and immunotherapeutic efficacy [7, 8]. This evidence concerns the gene CD4 and neoplasm.